A PHASE 1, RANDOMIZED, OPEN LABEL, 2-WAY CROSSOVER STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE SUBJECTS
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2019
Price : $35 *
At a glance
- Drugs PF 6651600 (Primary) ; Ethinylestradiol; Levonorgestrel
- Indications Alopecia areata; Crohn's disease; Rheumatoid arthritis; Ulcerative colitis; Vitiligo
- Focus Pharmacokinetics
- Sponsors Pfizer
- 14 Dec 2018 Status changed from recruiting to completed.
- 12 Nov 2018 Planned End Date changed from 26 Nov 2018 to 23 Nov 2018.
- 02 Oct 2018 Planned End Date changed from 1 Nov 2018 to 26 Nov 2018.